Scrip is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Cabaletta Bio Inc. raised $50mm through its Series B round from first-time buyers Deerfield Management, Boxer Capital (Tavistock), Redmile Group, and Cormorant Capital, along with returning investors Adage Capital, 5AM Ventures, and an undisclosed public equity health care investor. Cowen was the placement agent. Cabaletta is developing chimeric autoantibody receptor (CAAR) T-cell therapies to treat B cell-mediated autoimmune diseases based on CART technology in-licensed from the University of Pennsylvania. Series B proceeds will help the company establish translational research and advanced manufacturing capabilities to support pipeline development, including work on lead candidate DSG3-CAART for mucosal pemphigus vulgaris (IND submission is expected later this year).
Gene Therapy, Cell Therapy
Already a Strategic Transactions subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?